劉新垣，男，湖南人，分子生物學家，抗癌藥物戰士，湖南人，1952年南開大學畢業，後任職於河北醫科大學。1957始工作於中國科學院上海生物化學與細胞生物學研究所。1983-1984年美國羅氏研究所訪問學者。1991年當選中科院院士，1992年當選烏克蘭科學院院士，2001年當選第三世界科學院院士，2019年當選中國醫學科學院院士。發表論文400多篇，編有劉新垣論文集16捲，獲國家各種獎40多項，1991年獲國家兩部、一委突出貢獻獎，1996年獲國家科技進步二等獎一次，1997年又獲國家科技進步二等獎一次，2001年獲香港何梁何利獎。在國際上首創癌症的靶向基因–病毒治療理論，獲得很大成就。2019年世界癌症日（2月4日）被中國最大的生命科學、生物門戶網站，生物谷，評劉新垣為癌症發展史上里程碑式的人物。 

Xin-Yuan Liu, male, born in HuNan province, molecular biologist, fighter of antitumor, graduated from NanKai University in 1952, then worked in HeBei Medical College. Since 1957, he worked in the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences. From 1983 to 1984, he went to USA and worked as visiting scientist in the Roche Institute of Mol. Biol. He was elected as a member of the Chinese Academy of Sciences in 1991, foreign member of the National Academy of Sciences of Ukraine in 1992 and member of the Third World Academy of Sciences (TWAS) in 2001, member of the Chinese Medical Academy of Science in 2019.  In addition, he published more than 400 papers which were complied in 16 volumes Xin-Yuan Liu’s collected paper, got academic honor more than 40 items national an autostanding scientist award in 1991, national second award one time in 1996, another time in 1997 (totally two times), got Hong Kong HLHL award in 2001. He innovate the strategy of Cancer Targeting of Gene-Viro-Therapy, and got great success which was awarded in 2019 in the antitumor day (4, February) for Xin-Yuan Liu as a milestone man for antitumor science by a Chinese big biological, biomedical network, Biological Corner.

上海生物化學與細胞生物學研究所（簡稱上海生化與細胞所）成立於2000年5月，由原中國科學院上海生物化學研究所與原中國科學院上海細胞生物學研究所整合而成。生化與細胞所是我國生命科學領域最具科研實力和影響力的國立研究機構之一。經歷半個世紀的風雨和幾代科學家的艱苦創業和奮鬥，研究所（它的前身）先後取得了人工合成牛胰島素、人工全合成酵母丙氨酸轉移核糖核酸、卵母細胞的受精成熟和單性生殖、家魚的人工繁殖等具有重大國際影響的原創性成果，獲得國家自然科學一等獎、科技進步一等獎等等數次。不僅在國內享有崇高的科學和社會聲望，也為國際同行所矚目。

Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Sciences (CAS). It was established in 2000 through the merger of Shanghai Institute of Biochemistry (founded in 1958) and Shanghai Institute of Cell Biology (founded in 1950). Both of the former institutions had contributed to scientific advances over the last century including the total synthesis of crystalline bovine insulin, the total synthesis of yeast alanine tRNA, the artificial propagation of domestic fresh-water fish and artificial monogenesis of amphibian oocytes. Based on their rich academic experience, SIBCB has been an important national research base since its establishment with the pioneered and outstanding research programs in the area of biochemistry, molecular biology and cell biology. As a nation-renowned institution, SIBCB seeks preeminence in exploring the fundamental knowledge about human diseases, and applying that knowledge to promote the public health. It is dedicated to fostering innovative discoveries and inspiring an exciting education culture for nurturing future talents.

比諾獎產品PD-1抗體的抗癌效果更好的藥物，它甚至可全部消滅移植性腫瘤

Drug with Much Higher Antitumor Effect than that of Nobel Prize Product PD-1 Antibody till Completely Elimination the Xenograft Tumor